Enhancing Clinical Trial Patient Matching through Knowledge
Augmentation with Multi-Agents
HanwenShi JinZhang KunpengZhang
UniversityofMaryland PiHealth UniversityofMaryland
hwshi@umd.edu Jin.Zhang@pihealth.ai kpzhang@umd.edu
Abstract Theseapproachesarealsohighlysensitivetovaria-
tionsinhowpatientandtrialdataareexpressedin
Matchingpatientseffectivelyandefficientlyfor naturallanguageacrossdifferentsources. Simple
clinicaltrialsisasignificantchallengedueto
machine learning models often struggle with the
the complexity and variability of patient pro-
loadofinformationandthelowdensityofrelevant
files and trial criteria. This paper presents a
sentencesinlengthyelectronichealthrecord(EHR)
novel framework, Multi-Agents for Knowl-
edgeAugmentation(MAKA),designedtoen- data. They usually underperform when dealing
hance patient-trial matching by dynamically withcomplexeligibilitycriteriaorinconsistentdata
supplementing matching prompts with exter- formats,resultingininefficienciesandmismatches
nal,domain-specificknowledge. TheMAKA thatcannegativelyimpacttrialoutcomes(Kadam
architecture consists of five key components:
etal.,2016).
a knowledge probing agent that detects gaps
The emergence of of Large Language Models
indomainknowledge,anavigationagentthat
managesinteractionsamongmultiplespecial- (LLMs)offersapromisingopportunitytoimprove
izedknowledgeaugmentationagents,aknowl- patientmatching. LLMs,suchasGPT-4(Achiam
edgeaugmentationagentthatincorporatesrel- etal.,2023), usuallypossessalargetextwindow
evant information into patient-trial matching andadvancednaturallanguageunderstandingca-
prompts,asupervisionagentaligningtheout-
pabilities(Karanikolasetal.,2023),whichenable
putsfromotheragentswiththeinstructionsand
themprocesscomplextrailcriteriaandpatientdata
amatchingagentmakingthefinalselectionde-
effectively. However,theirgeneralknowledgemay
cision. This approach enhances the accuracy
not always be sufficient for knowledge-intensive
andcontextualrichnessofpatientmatching,ad-
dressesinherentknowledgegapsinbothtrail taskslikepatientmatchinginclinicaltrials,where
criteriaandlargelanguagemodels(LLMs),and domain-specificexpertiseisrequired. Theknowl-
improvesthealignmentbetweenpatientchar- edgegapinherentinLLMsandmisssinginforma-
acteristicsandthecriteria.
tioninthepre-definedcriteriacanlimittheirper-
formance,highlightingtheneedforLLMaugmen-
1 Introduction
tationofspecializedmedicalknowledge(Shuster
Patientmatchingforclinicaltrialsreferstothepro- etal.,2021). WhileresearchindicatesthatLLMs
cessofidentifyingandenrollingparticipantswhose doencodemedicalknowledgeinaparameterized
healthprofilesalignwiththespecificeligibilitycri- form(Singhaletal.,2023),thisinformationcanbe
teria of a given clinical study. Efficient patient outdated or misaligned with the special needs of
matchingiscrucialtoacceleratingthedrugdevel- certainclinicaltrials.
opment process and reducing the overall cost of To address these limitations, we present a new
clinicaltrials. Itprovidesanopportunityforpartic- frameworkcalled: Multi-AgentsforKnowledge
ipantstoaccessexperimentaltreatmentsthatcould Augmentation (MAKA). MAKA is a novel ar-
potentiallyimprovetheirhealthoutcomesand,in chitecturedesignedtoenhancethepatientmatch-
somecases,transformtheirqualityoflife. ing process by dynamically integrating domain-
Patientmatchingremainsachallengingtaskde- specificknowledgealignedwiththeuniquecontext
spite its critical role in clinical trials. Traditional of clinical trials. It consists of five main compo-
automatedmethods,whicharemostlyrule-based, nents: theKnowledgeProbingAgent,Navigation
dependheavilyonhand-craftedrulesandareoften Agent,KnowledgeAugmentationAgent,Supervi-
time-consuming(Brøgger-Mikkelsenetal.,2020). sionAgentandMatchingAgent. Byleveragingthis
1
4202
voN
22
]AM.sc[
1v73641.1142:viXramulti-agentframework,MAKAeffectivelyidenti- modelsize.
fiesandfillsknowledgegaps,enhancingtheLLM’s Incontrast,otherstudieshavefocusedontrial-
ability to understand complex eligibility criteria centricpatientmatching,typicallyusingpublicdei-
and patient profiles. This leads to an average im- dentifieddatasetsduetoHIPAA-relateddatacon-
provementof3%onaccuracyand6%onF1-score straints. Wornowetal.(2024)developedaLLM-
acrossvariouspatientselectioncriteria,withupto based system with a two-stage retrieval pipeline
a 10% boost in more knowledge-intensive cases. toidentifysuitablepatientsfortrialsusingazero-
Overall, our framework shows significant poten- shot prompt approach. It reduces token process-
tialsforachievingmoreaccuratepatientmatching. ing costs while outperforming existing state-of-
the-artmodelsonthen2c22018cohortselection
2 RelatedWork
benchmark(Stubbsetal.,2019). Likewise,Beattie
etal.(2024)appliedaCoTstrategyinaRetrieval-
2.1 ClinicalTrailPatientMatching
AugmentedGeneration(RAG)(Lewisetal.,2020)
Traditional patient matching systems rely on
system using GPT-3.5 Turbo and GPT-4, demon-
query-based structured databases, such as Crite-
strating results comparable to those of Wornow
ria2Query(Yuanetal.,2019),orhandcraftedrule-
etal.(2024).
basedapproacheslikeRBC(Oleyniketal.,2019).
Theseworkscollectivelyhighlightthepotential
However,thesemethodsstruggletohandleunstruc-
ofLLMsinclinicaltrialmatching. However,exist-
turedfree-textdataandarehighlysensitivetovari-
ingapproachesdirectlyemployLLMswithoutver-
ationsinformattingandverbalexpressions. Unfor-
ifyingwhetherthetrialcriteriaaresufficientlyun-
tunately,asignificantportionofEHRsconsistsof
derstoodbythemodel(WebsonandPavlick,2021)
free-text,includingclinicalnotes,surgicalrecords,
or whether there are gaps in the model’s knowl-
radiologyreports,pathologyreportsandsoon(Sun
edge(Lewisetal.,2020). Ourworkfitswithinthe
etal.,2018). Thus,theeffectivenessandscalabil-
trial-centricpatientmatchingliteratureandmakes
ityoftraditionalmethodsaresignificantlylimited,
anovelcontributionbyautomaticallyidentifying
makingthemunsuitableforfuturepatientmatching
andaddressingthesegaps,therebyenhancingthe
tasks.
accuracypatientmatching.
RecentadvancementsinLLMshaveshownre-
markable capabilities in directly processing free-
2.2 LLM-basedMulti-Agents(LLM-MA)
text clinical trial criteria, offering scalable solu-
tions without the need for extensive rule-based LLM-MAhaveseenrapiddevelopmentacrossvar-
preprocessing. Many Studies have applied these iousdomains,drivenbythepromisingpotentialof
models to patient-centric trial matching tasks us- LLMs as autonomous agents. Guo et al. (2024)
ing real-world data. For instance, Nievas et al. provide a comprehensive overview of recent ad-
(2024) fine-tuned the open-source Llama 2 (Tou- vancements in LLM-MA applications, categoriz-
vron et al., 2023) to automate patient matching. ingthemintotwoprimaryareas: Problem-Solving
However, fine-tuning LLMs is computationally andWorldSimulation. Problem-solvingLLM-MA
expensive, promptingalternativeapproachesthat systemsexplorethecapabilitiesofagentswithspe-
leveragefrozenmodels. Jinetal.(2023)introduced cialized expertise, enabling them to outperform
TrialGPT, a patient-centric matching framework single-agent LLM systems through collaborative
that assesses patient eligibility on a criterion-by- efforts. For instance, Wang et al. (2024) pro-
criterion basis, filtering out ineligible trials and posed Mixture-of-Agents, a layered multi-agent
rankingpotentiallyeligibleones. Theirresultsin- architecture that achieves state-of-the-art perfor-
dicated a strong correlation between TrialGPT’s manceinbenchmarkslikeAlpacaEval2.0(Dubois
predictionsandexpertclinicianjudgments,achiev- etal., 2024). Similarly, Honget al.(2023)intro-
ingaccuracyatthecriterionlevelsimilartohuman ducedMetaGPT,ameta-programmingframework
experts. Similarly, Gupta et al. (2024) proposed thatintegrateshuman-liketaskdecompositionand
OncoLLM, an end-to-end pipeline that converts workflows,outperformingGPT-4invariouscode
trialcriteriaintoconversationalpromptsanduses generationtasks.
aChain-of-Thought(CoT)(Weietal.,2022)rea- Inthehealthcaredomain,theuseofLLM-MA
soningstrategy. OncoLLMoutperformsGPT-3.5 systemsisemerging. TRIAGEAGENT(Luetal.,
while underperforms GPT-4, despite its smaller 2024)utilizesLLMsforrole-playinginteractions,
2Figure1: TheworkflowofMAKAframework
incorporating self-confidence and early-stopping Agentforfurtherprocessing.
mechanismsinmulti-rounddiscussionstoimprove Navigation Agent: In the MAKA framework,
document reasoning and classification precision multiplespecializedaugmentationagentsareavail-
fortriagetasks. Tangetal.(2023)uses multiple able to enrich the criterion with domain-specific
LLM-basedagentsasdomainexpertstocollabora- knowledge. TheNavigationAgentdeterminesthe
tivelyanalyzemedicalreportsandreachconsensus mostsuitableaugmentationagentforthetaskand
on medical diagnoses. To the best of our knowl- routestheworkflowaccordingly.
edge, this is the first study to leverage LLM-MA KnowledgeAugmentationAgent: Thiscompo-
for cohort selection in clinical trials. Our frame- nentenrichesthecriterionwithrelevant,domain-
workleveragesLLM-MAagencytodynamically specific information from different source. For
augmentpatient-trialmatchingwithtailoredknowl- instance, the Retrieval Agent (Lewis et al.,
edge,therebyenrichingthecontextualunderstand- 2020)retrievesinformationfromindexedmedical
ingofpatientprofilesandachievingbetterpatient databases,theOnlineSearchAgentgatherssupple-
matchingresults. mentaryknowledgefromonlinesources, andthe
Self-AugmentAgentleveragestheLLM’sintrinsic
3 Methods knowledgetorefinetheoriginalcriterion.
SupervisionAgent: Actingasasupervisor,this
Weautomatedecomposedpatient-matchingwork-
agentensuresthattheaugmentedcriterionaligns
flows by utilizing the ability of LLMs to process
withtheoriginalinstructions. Forexample,theaug-
andgeneratecomplexnaturallanguage. Thepro-
mentedoutputmustretainverbatimelementsfrom
posedframework,illustratedinFigure1,comprises
theoriginalcriterion. Thissupervisorymechanism
five interconnected components, each with a dis-
enhancestheframework’sinstruction-followingca-
tinctroleinensuringrobustautomation.
pabilityandmaintainsconsistency.
Knowledge Probing Agent: This component
Matching Agent: Finally, with either the aug-
identifiesknowledgegaps, bothin termsofmiss-
mented or unaugmented criterion, as determined
inginformationincriteriaanddeficienciesinthe
bytheKnowledgeProbingAgent,theMatching
LLM’sunderstandingofclinicaltrialsandpatient
Agent evaluates patient eligibility in a zero-shot
characteristics. Byemployingprompt-basedself-
manner.
probingtechniques,inspiredbySELFREF(Kada-
vath et al., 2022) and MOREINFO (Feng et al., 4 Evaluation
2023), the agent evaluates its own responses for
4.1 DataDescription
correctnessandconsistency.Iftheagentdetermines
thattheoriginalcriterionisdetailedandunderstand- WeusethedatasetfromTrack1ofthe2018n2c2
ableenoughforotheragents,thecriterionwillbe challenge(Stubbsetal.,2019),whichiscommonly
directlyforwardedtotheMatchingAgent. Other- used for evaluating patient matching in clinical
wise,thecriterionisforwardedtotheNavigation trials. The dataset consists of 288 de-identified
3Accuracy Precision Recall F1-score
Criteria
Zero-shot CoT MAKA Zero-shot CoT MAKA Zero-shot CoT MAKA Zero-shot CoT MAKA
ABDOMINAL 0.858 0.868 0.847 0.893 0.897 0.944 0.701 0.729 0.626 0.785 0.804 0.753
ADVANCED-CAD 0.854 0.854 0.868 0.895 0.872 0.929 0.853 0.882 0.841 0.873 0.877 0.883
ALCOHOL-ABUSE 0.969 0.969 0.976 0.529 0.545 0.667 0.900 0.600 0.600 0.667 0.571 0.632
ASP-FOR-MI 0.861 0.875 0.885 0.899 0.908 0.919 0.930 0.939 0.939 0.915 0.923 0.929
CREATININE 0.802 0.802 0.885 0.664 0.667 0.812 0.934 0.925 0.896 0.776 0.775 0.852
DIETSUPP-2MOS 0.764 0.781 0.785 0.704 0.717 0.721 0.940 0.953 0.953 0.805 0.818 0.821
DRUG-ABUSE 0.941 0.920 0.993 0.469 0.395 0.882 1.000 1.000 1.000 0.638 0.566 0.938
ENGLISH 0.976 0.986 0.983 0.985 0.989 0.996 0.989 0.996 0.985 0.987 0.992 0.991
HBA1C 0.840 0.830 0.878 0.722 0.702 0.807 0.892 0.902 0.863 0.798 0.790 0.834
KETO-1YR 0.993 0.990 0.993 - - - - - - - - -
MAJOR-DIABETES 0.833 0.826 0.847 0.851 0.831 0.873 0.840 0.853 0.840 0.845 0.842 0.856
MAKES-DECISIONS 0.920 0.924 0.931 0.985 0.985 0.996 0.931 0.935 0.931 0.957 0.959 0.963
MI-6MOS 0.885 0.872 0.927 0.434 0.396 0.571 0.885 0.808 0.769 0.582 0.532 0.656
Average 0.884 0.883 0.909 0.727 0.715 0.822 0.894 0.870 0.846 0.785 0.769 0.828
Table1: Criterion-LevelComparisonAcrossDifferentMethods
patients,eachhavingbetween2to5unstructured criteriathathadatleast100patientsmeetingthem,
longitudinal clinical notes in American English. resultingin28eligiblepatientsfromatotalcohort
Theentirecorpuscontains781,006tokens,withan of 288. We then evaluated our method’s on this
averageof2,711tokensperpatient. Thechallenge newsynthetictrailinidentifyingeligiblepatients
simulates a synthetic clinical trial with 13 prede- andreportedthefindings.
fined inclusion criteria, resulting in 3744 patient-
criteriapairsintotal. Thedetailedcriteriacanbe 4.3 Results
foundinTable4. Foreachpatient-criteriapair, a
4.3.1 Criterion-LevelPerformance
binarylabelisprovided,indicatingwhetherthepa-
Table 1 shows the performance of three
tient "MET" or "NOT MET" the criterion. Two
approaches—Zero-shot,CoT, MAKA—across
annotatorswithmedicalbackgroundlabeledthese
multiple individual criteria. Our results indicate
data. Thedisagreementsbetweenthetwoannota-
that while the CoT method slightly outperforms
torswereresolvedbyanindependentMDtoestab-
Zero-shot in Accuracy and Recall, MAKA
lishthefinalgroundtruthlabels.
consistently achieves higher scores, particularly
in Accuracy (0.909) and Precision(0.822) on
4.2 BaselineandMetrics
average. TheF1-scoreofMAKA(0.828)suggests
Previous research has demonstrated the superior- abalancedperformanceacrosscriteria,althoughit
ity of LLM-based methods over traditional rule- fallsslightlybehindinafewspecificcasessuchas
based systems; hence, this study focuses exclu- "ABDOMINAL"and"English".
sively on LLM-based benchmarks. We include TheMAKA-augmentedcriteria,presentedinTa-
twoapproaches: thezero-shotmethodwithhand- ble6,demonstratesignificantimprovementsover
crafted criteria (Wornow et al., 2024), as shown the baseline human-redefined criteria outlined in
in Table 5, and a Chain-of-Thought (CoT) ap- Table5fromWornowetal.(2024). Theseenhance-
proach(Beattieetal.,2024)usingtheoriginalcrite- mentsprimarilyfocusonprovidingexplicitclari-
ria. Inlinewithpriorliterature,wereportaccuracy, ficationsanddetailedexpansionsofkeyconcepts,
precision,recall,andF1-scoreforthisbinaryclas- enabling LLMs to better align with trial require-
sificationtask. ments. Forexample,MAKAsupplementsnormal
Previousstudieshaveprimarilyfocusedoneval- ranges for criteria like "HBA1C" and "CREATI-
uating classification performance at the individ- NINE" across diverse demographic groups. And
ual criterion level, often overlooking the overall theyarealsothecriteriathatbenefitthemostfrom
patient-trialassessment. Inthisstudy,weaddress MAKA’saugmentation. Additionally,MAKApro-
thisgapbyexaminingpatient-trialselectionperfor- videsamorecomprehensivedefinitionforcriteria
mance. Specifically,apatientiseligibleforthetrial like"MAJOR-DIABETES,"andusemorewidely
onlyifallinclusioncriteriaaremet. However,no recognizedterminology,"heartattack",toexplain
patientinthen2c2datasetsatisfiedall13criteria. clinicalterms"MyocardialInfarction(MI)". These
Tomitigatethis,wesynthesizeatrailwithselected refinementsenhancetheabilityofLLMstomatch
4patientsfromclinicalnoteswritteninavarietyof in LLM. Moreover, the Navigation Agent con-
styles,resultinginnotableperformancegainsfor sistently determined that all criteria could be suf-
thesecriteria. ficiently augmented by the Self-Augmentation
Agent, with no need to employ external retrieval
Metric Zero-shot CoT MAKA oronlinesearchaugmentation. Thesefindingssug-
Accuracy 0.8924 0.9201 0.9306 gestthatthedataset’ssimplicitymayhavelimited
Precision 0.4615 0.5676 0.6333 the full utilization of MAKA’s modular capabili-
Recall 0.6429 0.7500 0.6786
ties.
F1-Score 0.5373 0.6462 0.6552
Table2:Trial-LevelComparisonAcrossDifferentMeth- 6 Conclusion
ods
In this paper, we introduced MAKA, a frame-
work designed to automate decomposed patient-
4.3.2 Trial-LevelPerformance matching workflows by leveraging the advanced
natural language understanding capabilities of
The result of trail-levle analysis can be found in
LLMs. The framework’s modular design incor-
Table2. Atthetriallevel, whereapatient’seligi-
porates five key components—Knowledge Prob-
bilityisdeterminedbysatisfyingallselectedcrite-
ing Agent, Navigation Agent, Knowledge Aug-
ria,MAKAoutperformsbothZero-shotandCoT.
mentationAgent,SupervisionAgent,andMatch-
MAKA achieves the highest Accuracy (0.9306),
ingAgent—eachcontributingtosystematicknowl-
Precision (0.6333)and F1-score (0.6552) but un-
edgeaugmentationandrobustdecision-makingin
derperformCoTonRecall. Thetrail-levelresults
patient-trailmatchingsettings.
further validate MAKA’s capability in maintain-
WedemonstratedthatMAKAsignificantlyim-
ingahigherbalancebetweenidentifyingeligible
proves patient-matching performance at both the
patientsandminimizingpatient-filteringload
criterion and trial levels. Compared to baseline
OurfindingssuggestthatMAKAeffectivelycan
approaches like Zero-shot and Chain of Thought
effectivelyidentifiesandaddressesknowledgegaps
(CoT), MAKA achieves notable gains in Accu-
in LLMs for trial-centric patient matching. By
racy,Precision,andF1-score,particularlywhenap-
leveraging agent-augmented criteria, MAKA en-
pliedtocomplexorambiguouscriteria. Byenrich-
hances LLMs’ understanding of clinical trial re-
ingclinicalcriteriawithdomain-specificinsights,
quirements. Anditachievesabetterperformance
MAKAconsistentlyoutperformsalternativeswhile
on both minimizing manual selection efforts and
maintainingabalancebetweenprecisionandrecall.
accuratelyidentifyingeligiblepatients.
Furtherinvestigationofagentbehaviorsindicates
thattheperformanceimprovementsprimarilystem
5 Limitations
fromfillingtheknowledgegapsexistinginthecri-
Onesignificantlimitationofthisstudyliesinthe teria,ratherthaninLLMs.
datasetusedforevaluation. Then2c2dataset,the Ourresultshighlightthepracticalbenefitsofaug-
mostcommonlyused,publiclyavailabledatasetfor mentingLLMcapabilitieswithastructuredmuti-
thecohortselectiontask,isrelativelysmallinsize agentworkflowforknowledgeenhancement. For
and contains criteria that are neither particularly example,MAKA-augmentedcriteriaimprovesun-
complexnorchallengingforLLM-basedprocess- derstandingofclinicaltrialrequirementsbyalign-
ing. As a result, while MAKA is designed as a ing better with diverse patient note styles and
generalframeworkcapableofhandlingbothsim- heterogeneity of criterion. The results validate
pleandcomplexcriteria,thedataset’slimitations MAKA’s potential for real-world deployment in
restrict our ability to thoroughly evaluate its gen- clinicaltrialworkflows.
eralizabilityacrossabroaderrangeofclinicaltrial ItisworthnotingthatthedesignofMAKAsup-
requirements. portsthefuturedevelopmentofahuman-AIcollab-
An additional observation from our experi- orationsystem. Forthetrial-centricpatientmatch-
mentsisthattheKnowledgeProbingAgentpre- ing task, the volume of criterion-supervision per-
dominantly identified gaps in the criteria them- formedbythesupervisoryagentisrelativelysmall
selves—primarily issues of clarity or insufficient and can be efficiently handled by human experts
detail—rather than uncovering knowledge gaps withminimaltimeinvestment. Exploringhowhu-
5manscanfurtherenhanceandfacilitatethissystem Shashi Kant Gupta, Aditya Basu, Mauro Nievas,
presentsaninterestingdirectionforfutureresearch. Jerrin Thomas, Nathan Wolfrath, Adhitya Rama-
murthi, Bradley Taylor, Anai N Kothari, Regina
Toaddressthelimitationsofthisstudyandvali-
Schwind, Therica M Miller, et al. 2024. Prism:
dateMAKA’sgeneralizability,futureworkcould
Patient records interpretation for semantic clinical
alsofocusonevaluatingtheframeworkusingmore trialmatchingusinglargelanguagemodels. arXiv
challengingdatasets,suchasthoseinvolvingoncol- preprintarXiv:2404.15549.
ogytrialmatchingwhichcontainshighlycomplex
Sirui Hong, Xiawu Zheng, Jonathan Chen, Yuheng
criteriaorthosewithacohortoflargersize. Testing Cheng,JinlinWang,CeyaoZhang,ZiliWang,Steven
MAKAinthesscontextswouldnotonlyprovide KaShingYau,ZijuanLin,LiyangZhou,etal.2023.
amorerigorousassessmentofitscapabilitiesbut Metagpt:Metaprogrammingformulti-agentcollabo-
rativeframework. arXivpreprintarXiv:2308.00352.
also demonstrate its potential to address critical
real-worldchallengesinclinicaltrialrecruitment. Qiao Jin, Zifeng Wang, Charalampos S Floudas,
Fangyuan Chen, Changlin Gong, Dara Bracken-
Acknowledgments Clarke,ElisabettaXue,YifanYang,JimengSun,and
ZhiyongLu.2023. Matchingpatientstoclinicaltrials
WegratefullyacknowledgesupportfromtheOpe- withlargelanguagemodels. ArXiv.
nAIResearchAccessProgram,whichprovidedac-
Rashmi Ashish Kadam, Sanghratna Umakant Borde,
cesstoadvancedlanguagemodelsthatwereinstru-
Sapna Amol Madas, Sundeep Santosh Salvi, and
mentalindevelopingandevaluatingtheframework SnehaSaurabhLimaye.2016. Challengesinrecruit-
presentedinthiswork. Thissupportsignificantly mentandretentionofclinicaltrialsubjects. Perspec-
tivesinclinicalresearch,7(3):137–143.
facilitatedtheexperimentsandanalysesconducted
forthisresearch.
SauravKadavath,TomConerly,AmandaAskell,Tom
Henighan, Dawn Drain, Ethan Perez, Nicholas
Schiefer,ZacHatfield-Dodds,NovaDasSarma,Eli
References Tran-Johnson, et al. 2022. Language models
(mostly) know what they know. arXiv preprint
JoshAchiam,StevenAdler,SandhiniAgarwal,Lama arXiv:2207.05221.
Ahmad, Ilge Akkaya, Florencia Leoni Aleman,
DiogoAlmeida,JankoAltenschmidt,SamAltman, NikitasKaranikolas,EiriniManga,NikolettaSamaridi,
ShyamalAnadkat,etal.2023. Gpt-4technicalreport. EleniTousidou,andMichaelVassilakopoulos.2023.
arXivpreprintarXiv:2303.08774. Largelanguagemodelsversusnaturallanguageun-
derstanding and generation. In Proceedings of the
JacobBeattie,SarahNeufeld,DanielYang,Christian 27thPan-HellenicConferenceonProgressinCom-
Chukwuma,AhmedGul,NeilDesai,SteveJiang,and putingandInformatics,pages278–290.
MichaelDohopolski.2024. Utilizinglargelanguage
modelsforenhancedclinicaltrialmatching: Astudy PatrickLewis,EthanPerez,AleksandraPiktus,Fabio
onautomationinpatientscreening. Cureus,16(5). Petroni,VladimirKarpukhin,NamanGoyal,Hein-
richKüttler, MikeLewis, Wen-tauYih, TimRock-
Mette Brøgger-Mikkelsen, Zarqa Ali, John R Zibert, täschel,etal.2020. Retrieval-augmentedgeneration
AndersDanielAndersen,andSimonFrancisThom- forknowledge-intensivenlptasks. AdvancesinNeu-
sen.2020. Onlinepatientrecruitmentinclinicaltri- ralInformationProcessingSystems,33:9459–9474.
als: systematicreviewandmeta-analysis. Journalof
medicalInternetresearch,22(11):e22179. MengLu,BrandonHo,DennisRen,andXuanWang.
2024. Triageagent: Towardsbettermulti-agentscol-
YannDubois,BalázsGalambosi,PercyLiang,andTat- laborationsforlargelanguagemodel-basedclinical
sunori B Hashimoto. 2024. Length-controlled al- triage. InFindingsoftheAssociationforComputa-
pacaeval: Asimplewaytodebiasautomaticevalua- tionalLinguistics: EMNLP2024,pages5747–5764.
tors. arXivpreprintarXiv:2404.04475.
MauroNievas,AdityaBasu,YanshanWang,andHrit-
ShangbinFeng,WeijiaShi,YuyangBai,VidhishaBal- urajSingh.2024. Distillinglargelanguagemodels
achandran,TianxingHe,andYuliaTsvetkov.2023. for matching patients to clinical trials. Journal of
Knowledgecard: Fillingllms’knowledgegapswith theAmericanMedicalInformaticsAssociation,page
plug-inspecializedlanguagemodels. arXivpreprint ocae073.
arXiv:2305.09955.
Michel Oleynik, Amila Kugic, Zdenko Kasácˇ, and
TaichengGuo,XiuyingChen,YaqiWang,RuidiChang, MarkusKreuzthaler.2019. Evaluatingshallowand
ShichaoPei,NiteshVChawla,OlafWiest,andXi- deeplearningstrategiesforthe2018n2c2sharedtask
angliangZhang.2024. Largelanguagemodelbased onclinicaltextclassification. JournaloftheAmeri-
multi-agents: Asurveyofprogressandchallenges. canMedicalInformaticsAssociation,26(11):1247–
arXivpreprintarXiv:2402.01680. 1254.
6KurtShuster,SpencerPoff,MoyaChen,DouweKiela, A Criteria
and Jason Weston. 2021. Retrieval augmentation
reduceshallucinationinconversation. arXivpreprint A.1 N2C2CriteriaStatistics
arXiv:2104.07567.
Criterion MetCount NotMetCount
KaranSinghal,ShekoofehAzizi,TaoTu,SSaraMah-
davi,JasonWei,HyungWonChung,NathanScales, ABDOMINAL 107 181
AjayTanwani,HeatherCole-Lewis,StephenPfohl, ADVANCED-CAD 170 118
etal.2023. Largelanguagemodelsencodeclinical ALCOHOL-ABUSE 10 278
knowledge. Nature,620(7972):172–180. ASP-FOR-MI 230 58
CREATININE 106 182
Amber Stubbs, Michele Filannino, Ergin Soysal, DIETSUPP-2MOS 149 139
Samuel Henry, and Özlem Uzuner. 2019. Cohort DRUG-ABUSE 15 273
ENGLISH 265 23
selection for clinical trials: n2c2 2018 shared task
HBA1C 102 186
track1. JournaloftheAmericanMedicalInformatics
KETO-1YR 1 287
Association,26(11):1163–1171.
MAJOR-DIABETES 156 132
MAKES-DECISIONS 277 11
WenchengSun,ZhipingCai,YangyangLi,FangLiu,
MI-6MOS 26 262
ShengqunFang,andGuoyanWang.2018. Datapro-
cessingandtextminingtechnologiesonelectronic
Table3: CountsofEligibleandIneligiblePatientsfor
medical records: a review. Journal of healthcare
EachCriterion
engineering,2018(1):4302425.
Xiangru Tang, Anni Zou, Zhuosheng Zhang, Ziming
A.2 N2C2OriginalCriteria
Li,YilunZhao,XingyaoZhang,ArmanCohan,and
MarkGerstein.2023. Medagents: Largelanguage
modelsascollaboratorsforzero-shotmedicalreason- Criteria Definition
DRUG-ABUSE Drugabuse,currentorpast.
ing. arXivpreprintarXiv:2311.10537.
ALCOHOL-ABUSE Currentalcoholuseoverweeklyrecommended
limits.
Hugo Touvron, Louis Martin, Kevin Stone, Peter Al- ENGLISH PatientmustspeakEnglish.
bert, Amjad Almahairi, Yasmine Babaei, Nikolay MAKES-DECISIONS Patientmustmaketheirownmedicaldecisions.
ABDOMINAL History of intra-abdominal surgery, small or
Bashlykov,SoumyaBatra,PrajjwalBhargava,Shruti largeintestineresection,orsmallbowelobstruc-
Bhosale, et al. 2023. Llama 2: Open founda- tion.
tion and fine-tuned chat models. arXiv preprint MAJOR-DIABETES Majordiabetes-relatedcomplications,suchas:
amputation, kidney damage, skin conditions,
arXiv:2307.09288. retinopathy,nephropathy,neuropathy.
ADVANCED-CAD Advanced cardiovascular disease, defined as
JunlinWang,JueWang,BenAthiwaratkun,CeZhang, twoormoreofthefollowing:medicationsfor
CAD,historyofmyocardialinfarction,angina,
andJamesZou.2024. Mixture-of-agentsenhances ischemia.
large language model capabilities. arXiv preprint MI-6MOS Myocardialinfarctioninthepast6months.
arXiv:2406.04692. KETO-1YR Diagnosisofketoacidosisinthepastyear.
DIETSUPP-2MOS Takenadietarysupplement(excludingVitamin
D)inthepast2months.
Albert Webson and Ellie Pavlick. 2021. Do prompt- ASP-FOR-MI Useofaspirintopreventmyocardialinfarction.
basedmodelsreallyunderstandthemeaningoftheir HBA1C AnyHbA1cvaluebetween6.5and9.5%.
CREATININE Serumcreatinine>upperlimitofnormal.
prompts? arXivpreprintarXiv:2109.01247.
Table4: Definitionsoftheoriginalcriteriainthen2c2
JasonWei,XuezhiWang,DaleSchuurmans,Maarten
dataset.
Bosma,FeiXia,EdChi,QuocVLe,DennyZhou,
etal.2022. Chain-of-thoughtpromptingelicitsrea-
soninginlargelanguagemodels. Advancesinneural
informationprocessingsystems,35:24824–24837.
MichaelWornow,AlejandroLozano,DevDash,Jenelle
Jindal, Kenneth W Mahaffey, and Nigam H Shah.
2024. Zero-shotclinicaltrialpatientmatchingwith
llms. arXivpreprintarXiv:2402.05125.
ChiYuan,PatrickBRyan,CaseyTa,YixuanGuo,Zi-
ran Li, Jill Hardin, Rupa Makadia, Peng Jin, Ning
Shang, Tian Kang, et al. 2019. Criteria2query: a
natural language interface to clinical databases for
cohortdefinition. JournaloftheAmericanMedical
InformaticsAssociation,26(4):294–305.
7A.3 RedefinedCriteria A.4 MAKA-AugementedCriteria
Criteria Definition Criteria Definition
ABDOMINAL Historyofintra-abdominalsurgery. Thiscouldincludeanyformofintra- ABDOMINAL Criteria:Historyofintra-abdominalsurgery,includingsmall/largeintestine
abdominalsurgery,includingbutnotlimitedtosmall/largeintestineresection resectionorsmallbowelobstruction.
orsmallbowelobstruction. Explanation:Intra-abdominalsurgeryinvolvesoperationsonorganswithin
ADVANCED-CAD Advancedcardiovasculardisease(CAD).Definedashaving2ormoreofthe theabdominalcavity(e.g.,stomach,intestines).Smallbowelobstructionrefers
following: (a)Taking2ormoremedicationstotreatCAD(b)Historyof toblockagesinthesmallintestinethatmayrequiresurgery.
myocardialinfarction(MI)(c)Currentlyexperiencingangina(d)Ischemia, ADVANCED-CAD Criteria:Advancedcardiovasculardisease(CAD)definedbyhavingtwoor
pastorpresent.Thepatientmusthaveatleast2ofthesecategories(a,b,c,d) moreofthefollowing:(a)Taking2ormoremedicationsforCAD,(b)History
tomeetthiscriterion,otherwisethepatientdoesnotmeetthiscriterion.For ofmyocardialinfarction(MI),(c)Currentangina,or(d)Ischemia(pastor
ADVANCED-CAD,bestrictinyourevaluationofthepatient–iftheyjusthave present).
cardiovasculardisease,thentheydonotmeetthiscriterion. Explanation:CADaffectsheartfunctionduetoblockedarteries.Definitions
ALCOHOL-ABUSE Currentalcoholuseoverweeklyrecommendedlimits. include:MI(heartattack),angina(chestpain),ischemia(reducedbloodflow),
ASP-FOR-MI Useofaspirinforpreventingmyocardialinfarction(MI). andspecificmedicationslikestatinsorbeta-blockers.AdiagnosisofCAD
CREATININE Serumcreatininelevelabovetheuppernormallimit. alonedoesnotqualifyasadvanced.
DIETSUPP-2MOS Consumptionofadietarysupplement(excludingvitaminD)inthepast2 ALCOHOL-ABUSE Criteria:Currentalcoholuseexceedingweeklyrecommendedlimits.
months.Toassessthiscriterion,gothroughthelistofmedicationsandsup- Explanation:Weeklylimits:upto14standarddrinks.Astandarddrinkis14g
plementstakenfromthenote.Ifasubstancecouldpotentiallybeusedasa ofpurealcohol(12ozbeer,5ozwine,or1.5ozspirits).
dietarysupplement(i.e.,itiscommonlyusedasadietarysupplement,even ASP-FOR-MI Criteria:Useofaspirintopreventmyocardialinfarction(MI).
ifitisnotexplicitlystatedasbeingusedasadietarysupplement),thenthe Explanation:AspirinreducesMIriskbypreventingclotsbutrequiresmedical
patientmeetsthiscriterion.Belenientandbroadinwhatisconsideredadietary advicetobalancebenefits(riskreduction)andpotentialsideeffects(e.g.,bleed-
supplement.Forexample,a’multivitamin’and’calciumcarbonate’should ing).
alwaysbeconsideredadietarysupplementiftheyareincludedinthislist. CREATININE Criteria:Serumcreatininelevelabovetheuppernormallimit.
DRUG-ABUSE Currentorpasthistoryofdrugabuse. Explanation:Creatininereflectskidneyfunction.Normallevelsvarybyage
ENGLISH PatientspeaksEnglish.AssumethatthepatientspeaksEnglish,unlessotherwise andgender(e.g., 0.6-1.2mg/dLforadultmales). Elevatedlevelssuggest
explicitlynoted.Ifthepatient’slanguageisnotmentionedinthenote,then potentialkidneyimpairment.
assumetheyspeakEnglishandthusmeetthiscriteria. DIETSUPP-2MOS Criteria:Consumptionofadietarysupplement(excludingVitaminD)inthe
HBA1C AnyhemoglobinA1c(HbA1c)valuebetween6.5%and9.5%. past2months.
KETO-1YR Diagnosisofketoacidosiswithinthepastyear. Explanation:Supplementsincludemultivitamins,calciumcarbonate,fishoil,
MAJOR-DIABETES Majordiabetes-relatedcomplication.Examplesof“majorcomplication”(as orherbalsupplementslikeginseng.ExcludesVitaminDexplicitly.
opposedto“minorcomplication”)include,butarenotlimitedto,anyofthe DRUG-ABUSE Criteria:Currentorpastdrugabusehistory.
followingthatarearesultof(orstronglycorrelatedwith)uncontrolleddiabetes: Explanation:Drugabuseincludesmisuseofpsychoactivesubstances,with
•Amputation•Kidneydamage•Skinconditions•Retinopathy•Nephropathy potentialconsequenceslikehealthissuesorlegalproblems.
•Neuropathy.Additionally,ifmultipleconditionstogetherimplyaseverecase ENGLISH Criteria:PatientmustspeakEnglish.
ofdiabetes,thencountthatasamajorcomplication. Explanation:EnglishproficiencyensureseffectiveparticipationinEnglish-
MAKES-DECISIONS Patientmustmaketheirownmedicaldecisions.Assumethatthepatientmakes basedtrials.AssumeEnglishproficiencyunlessnotedotherwise.
theirownmedicaldecisions,unlessotherwiseexplicitlynoted.Thereisno HBA1C Criteria:HemoglobinA1c(HbA1c)between6.5%and9.5%.
informationprovidedaboutthepatient’sabilitytomaketheirownmedical Explanation:HbA1cmeasuresaveragebloodsugarover2–3months.The
decisions,thenassumetheydomaketheirowndecisionsandthereforemeet rangeidentifiesdiabetespatientswithmoderatecontrol,excludingpoorlycon-
thiscriteria. trolledcases.
MI-6MOS Myocardialinfarction(MI)withinthepast6months. KETO-1YR Criteria:Diagnosisofketoacidosisinthepastyear.
Explanation:Ketoacidosisisaseriousconditionwithhighbloodketones,
Table5: RedefinedCriteria oftenrelatedtouncontrolleddiabetes.Symptomsincludenausea,confusion,
andrapidbreathing.
MAJOR-DIABETES Criteria:Majordiabetes-relatedcomplicationslikeamputation,kidneydamage,
orneuropathy.
Explanation:Includessignificanthealtheffects(e.g.,nephropathy,retinopathy)
stemmingfromuncontrolleddiabetes.Multipleminorcomplicationscombined
mayalsoqualify.
MAKES-DECISIONS Criteria:Patientmustmaketheirownmedicaldecisions.
Explanation:Thisassessescognitiveabilitytounderstandmedicaloptions,
communicatechoices,andappreciateconsequences.
MI-6MOS Criteria:Myocardialinfarction(MI)withinthepast6months.
Explanation:MIreferstoheartmuscledamagefromblockedbloodflow.
Assessviamedicalhistoryandrecordsconfirmingtheeventwithin6months.
Table6: AugmentedCriteriabyMAKA
8